Palvella Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Palvella Therapeutics Inc's ROI in the second quarter of 2026?
Palvella Therapeutics Inc recorded a cumulative net loss of $-62 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -40.75%.

Within the Healthcare sector 431 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3695, from total ROI ranking in the first quarter of 2026 at 4533.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	369.42 %	-	-	-	-
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	242	255	48	61	67
Return On Investment (TTM)	-40.75 %	-45.72 %	-66.83 %	-47.47 %	-87.99 %
PVLA's Overall Ranking	# 3695	# 4533	# 3824	# 4159	#
Seq. Investment Change TTM	40.42 %	72.74 %	-10.08 %	115.21 %	-
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-62	-49	-42	-33	-28

PVLA Company Profile >> Back to PVLA Roi Comparisons >> See Annual PVLA Return On Investment

Return On Investment PVLA's Ranking
Within:	No.
Industry	# 170
Sector	# 432
Overall	# 3695

Return On Investment Statistics
High	Average	Low
-7.63 %	-59.93 %	-202.06 %
(Sep 30 2018)		(Dec 31 2023)

Financial Statements
Palvella Therapeutics Inc's II. Quarter Investments	$ 242 Millions	PVLA's Balance sheet
Palvella Therapeutics Inc's II. Quarter Income	$ -22 Millions	Quarterly PVLA's Income Statement
PVLA's Income by Division		See PVLA's Income by Division

PVLA Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	48	76	27	59	103
Y / Y Investment Growth	-36.72 %	184.76 %	-54.58 %	-42.81 %	24.3 %
Net Income in Millions	-42	-17	-25	-33	-46
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-86.52 %	-22.88 %	-91.72 %	-56.49 %	-44.41 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PVLA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PVLA's Competitors
Subscribers only: Roi for Palvella Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for PVLA's Customers

Other Ratios
PVLA's Roa	PVLA's Inventory Turnover Ratio	PVLA's Growth Rates	PVLA's Dividend Statistics
	PVLA's Profitability Ratios	PVLA's Asset Turnover Ratio	PVLA's Dividend Growth
PVLA's Roe	PVLA's Valuation Ratios	PVLA's Financial Strength Ratios	PVLA's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-08-31T14:04:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.